ClearPoint Neuro Reports Third Quarter 2026 Results
Revenue growth included acquired IRRAflow products, while lower gross margin and higher expenses accompanied a wider quarterly loss.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ClearPoint Neuro (NASDAQ:CLPT) reported third-quarter 2026 revenue of $12.1 million, up 36% year over year, including acquired IRRAflow products. Neurosurgery navigation and therapy revenue rose 59% to $5.4 million; biologics and drug delivery increased 11% to $4.9 million. Capital equipment and software revenue grew 68% to $1.7 million.
Gross margin fell to 58% from 63%, while operating expenses rose 23% to $13.4 million. Net loss widened to $7.460 million, or $0.24 per share, from $5.891 million, or $0.21 per share. ClearPoint estimates 2026 revenue of $48.0 million to $50.0 million. Cash was $46.2 million at September 30, versus $45.9 million at year-end, following $22.0 million in net equity-offering proceeds; nine-month operating cash use was $20.094 million. A partner submitted its first formal biologics license application for Huntington's disease treatment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter revenue increased 36% year over year to $12.1 million, including acquired IRRAflow products.
- Moderate point. Forward-looking: it has not happened yet and may not happen.2026 revenue outlook is estimated by ClearPoint at $48.0 million to $50.0 million.
- Moderate pointNine-month gross profit rose to $21.525 million from $16.288 million in 2025.
- Moderate pointAt-the-market equity offering provided $22.020 million in net proceeds during the first nine months. 7.4% of market cap
- Moderate pointPartner regulatory milestone: one partner submitted its first formal biologics license application for Huntington's disease treatment.
6 minor points
- Minor pointNeurosurgery navigation and therapy revenue rose 59% to $5.4 million, primarily driven by acquired IRRAflow sales.
- Minor pointBiologics and drug delivery revenue grew 11% to $4.9 million, primarily from increased laboratory services.
- Minor pointCapital equipment and software revenue reached a record $1.7 million, up 68% year over year.
- Minor pointNine-month revenue increased to $35.083 million from $26.561 million in 2025.
- Minor pointCash and cash equivalents totaled $46.184 million at September 30, versus $45.923 million at December 31, 2025.
- Minor pointSpinal laser therapy research: ClearPoint is an industry partner in Dartmouth Health's five-year, $2.98 million NCI-funded program.
Negative
- Moderate pointThird-quarter net loss widened to $7.460 million, or $0.24 per share, from $5.891 million, or $0.21.
- Moderate pointGross margin fell to 58% from 63%, reflecting laboratory overhead and acquired-intangible amortization, partly offset by lower other costs.
- Moderate pointThird-quarter operating expenses increased 23% to $13.4 million, mainly driven by the IRRAS acquisition.
- Moderate pointNine-month operating cash use increased to $20.094 million from $11.845 million in 2025.
- Moderate pointEquity issuance dilutes holders: outstanding common shares rose to 32,051,494 at September 30 from 29,368,760 at year-end.
9 minor points
- Minor pointThird-quarter operating loss widened to $6.332 million from $5.276 million a year earlier.
- Minor pointThird-quarter interest expense increased to $1.446 million from $0.939 million a year earlier.
- Minor pointNine-month net loss widened to $28.349 million, or $0.94 per share, from $17.754 million, or $0.63.
- Minor pointNine-month operating loss widened to $25.054 million from $17.119 million in 2025.
- Minor pointNine-month interest expense increased to $4.241 million from $1.304 million in 2025.
- Minor pointAt-the-market issuance costs totaled $0.5 million during the first nine months.
- Minor pointLong-term notes payable, net increased to $50.840 million from $49.077 million at December 31, 2025.
- Minor pointNoncurrent operating lease liabilities rose to $22.661 million from $8.461 million at December 31, 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Spinal laser therapy program remains early-stage research, with validation and a clinical trial in its planned progression.
News Explained
ClearPoint reported
Key Figures
- Third-quarter revenue
- $12.1 million; +36%
- Three months ended September 30, 2026, year over year
- 2026 revenue estimate
- $48.0 million–$50.0 million
- Company estimate for full-year 2026
- Gross margin
- 58% vs. 63%
- Third quarter 2026 vs. third quarter 2025
- Operating expenses
- $13.4 million; +23%
- Third quarter 2026 year over year
- Net loss
- $7.460 million
- Three months ended September 30, 2026
- Cash and cash equivalents
- $46.2 million
- As of September 30, 2026
- ATM offering net proceeds
- $22.0 million
- Received during the nine months ended September 30, 2026
- Cash used in operating activities
- $20.1 million
- Nine months ended September 30, 2026
Previous Earnings Reports
-
Q2 revenue rose 18% and gross margin improved to 62%, while biologics revenue declined.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
at-the-market equity offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, CA / ACCESS Newswire / October 28, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026.
Third Quarter 2026 Highlights
- Reported third quarter revenue of
$12.1 million , representing36% overall growth, including the recently acquired IRRAflow Portfolio; - Neurosurgery navigation and therapy, which includes navigation, laser, drill and IRRAflow products, increased
59% to$5.4 million in the quarter; - Achieved record capital equipment and software revenue of
$1.7 million , representing68% growth in the quarter, including the recently acquired IRRAflow equipment; - Increased biologics and drug delivery revenue to
$4.9 million , an11% year-over-year increase; - First formal BLA was submitted by one partner for the treatment of Huntington's Disease;
- ClearPoint is an industry partner in a five-year,
$2.98 million competitively awarded NCI R01, led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases.¹ The program runs from benchtop through large subject validation to a clinical trial, using the ClearPoint Prism system. ClearPoint contributes technical, software development, and procedural expertise. This is early-stage research that supports our spine LITT roadmap; - Received net proceeds of
$22.0 million from the at-the-market equity offering program; and - Reported cash and cash equivalents of
$46.2 million as of September 30, 2026.
"Throughout 2026 we have continued to make substantial strategic progress in building our comprehensive drug delivery ecosystem, adding new biopharma partners, and assisting existing partners progress through the regulatory process globally," commented Joe Burnett, President and CEO at ClearPoint Neuro. "The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth. The
Business Outlook
The Company now estimates revenue in 2026 to be between
Financial Results - Quarter Ended September 30, 2026
Total revenue was
Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored preclinical and clinical trials utilizing our products, increased
Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint and IRRAflow systems, increased
Capital equipment and software revenue, consisting of sales of ClearPoint and IRRAflow reusable hardware and software and related services, increased
The Company achieved a gross margin of
Operating expenses were
At September 30, 2026, the Company had cash and cash equivalents totaling
¹ Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under award number R01CA307001. A total of
Teleconference Information
Investors and analysts are invited to listen to a live broadcast review of the Company's third quarter 2026 results on Wednesday, October 28, 2026 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=cPBDKSsR. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until November 27, 2026, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the meaning of the federal securities laws, including the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding: the Company's 2026 revenue guidance and other expectations regarding future financial performance, liquidity and capital resources; the expected adoption and growth of the Company's neurosurgery navigation and therapy products, including IRRAflow and laser therapy, and its capital equipment and software placements; the growth of the Company's biologics and drug delivery business, including preclinical services at ClearPoint Advanced Laboratories; the regulatory progress of the Company's biologics and drug delivery partners; the expansion of the Company's laser therapy program into spine; the development of the Company's product pipeline; and other statements of management's expectations, beliefs, plans, estimates or projections relating to the future. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "potential," "may," "will," "should," "could" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements.
Factors that could cause actual results to differ materially include, among others: the Company's ability to achieve broader market adoption of its products and services; the timing and outcome of its biologics and drug delivery partners' clinical trials and regulatory submissions; the Company's ability to maintain and expand its partner relationships; the risk that ClearPoint Advanced Laboratories may not achieve or maintain GLP compliance or generate revenue on anticipated timelines; the integration of acquired businesses, including IRRAS; changes in government regulation, reimbursement and funding; competition; supply chain disruptions; the Company's ability to fund its operations and service its indebtedness; and general economic, market and geopolitical conditions. For a more detailed description of the Company's risks and uncertainties, you are encouraged to review its documents filed with the SEC including the Company's recent filings on Form 8-K, Form 10-K and Form 10-Q, including the "Risk Factors" sections therein. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contact:
Investor Relations:
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
CLEARPOINT NEURO, INC.
Consolidated Statements of Operations
(in thousands, except for share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenue: | ||||||||||||||||
Product revenue | $ | 7,891 | $ | 5,361 | $ | 24,069 | $ | 16,649 | ||||||||
Service and other revenue | 4,184 | 3,500 | 11,014 | 9,912 | ||||||||||||
Total revenue | 12,075 | 8,861 | 35,083 | 26,561 | ||||||||||||
Cost of revenue | 5,016 | 3,261 | 13,558 | 10,273 | ||||||||||||
Gross profit | 7,059 | 5,600 | 21,525 | 16,288 | ||||||||||||
Research and development costs | 4,018 | 3,452 | 13,172 | 10,660 | ||||||||||||
Sales and marketing expenses | 5,532 | 3,838 | 19,015 | 11,691 | ||||||||||||
General and administrative expenses | 3,841 | 3,586 | 14,392 | 11,056 | ||||||||||||
Operating loss | (6,332 | ) | (5,276 | ) | (25,054 | ) | (17,119 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Other income (expense), net | 22 | (64 | ) | (20 | ) | (112 | ) | |||||||||
Interest income | 292 | 396 | 932 | 832 | ||||||||||||
Interest expense | (1,446 | ) | (939 | ) | (4,241 | ) | (1,304 | ) | ||||||||
Net loss before income taxes | (7,464 | ) | (5,883 | ) | (28,383 | ) | (17,703 | ) | ||||||||
Income tax (benefit) expense | (4 | ) | 8 | (34 | ) | 51 | ||||||||||
Net loss | $ | (7,460 | ) | $ | (5,891 | ) | $ | (28,349 | ) | $ | (17,754 | ) | ||||
Net loss per share attributable to common stockholders: | ||||||||||||||||
Basic and diluted | $ | (0.24 | ) | $ | (0.21 | ) | $ | (0.94 | ) | $ | (0.63 | ) | ||||
Weighted average shares outstanding: | ||||||||||||||||
Basic and diluted | 30,983,193 | 28,427,574 | 30,237,502 | 28,137,528 | ||||||||||||
CLEARPOINT NEURO, INC.
Consolidated Balance Sheets
(in thousands, except for par value and share data)
| September 30, | ||||||||
| 2026 | December 31, | |||||||
| (Unaudited) | 2025 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 46,184 | $ | 45,923 | ||||
Accounts receivable, net | 8,017 | 6,549 | ||||||
Inventory, net | 9,772 | 8,359 | ||||||
Prepaid expenses and other current assets | 2,741 | 2,769 | ||||||
Total current assets | 66,714 | 63,600 | ||||||
Property and equipment, net | 3,122 | 2,621 | ||||||
Operating lease right-of-use assets | 21,195 | 8,430 | ||||||
Goodwill | 7,472 | 7,472 | ||||||
Intangible assets, net | 12,412 | 13,922 | ||||||
Other assets | 1,813 | 1,702 | ||||||
Total assets | $ | 112,728 | $ | 97,747 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,060 | $ | 1,256 | ||||
Accrued compensation | 4,559 | 4,360 | ||||||
Other accrued liabilities | 2,502 | 2,786 | ||||||
Operating lease liabilities, current portion | 198 | 694 | ||||||
Contract liabilities, current portion | 1,550 | 1,669 | ||||||
Total current liabilities | 9,869 | 10,765 | ||||||
Operating lease liabilities, net of current portion | 22,661 | 8,461 | ||||||
Contract liabilities, net of current portion | 428 | 581 | ||||||
Long-term notes payable, net | 50,840 | 49,077 | ||||||
Accrued interest payable | 1,358 | 489 | ||||||
Deferred tax liabilities, net | 305 | 354 | ||||||
Total liabilities | 85,461 | 69,727 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 320 | 294 | ||||||
Additional paid-in capital | 269,639 | 238,995 | ||||||
Shares to be issued | 2,567 | 5,641 | ||||||
Accumulated deficit | (245,259 | ) | (216,910 | ) | ||||
Total stockholders' equity | 27,267 | 28,020 | ||||||
Total liabilities and stockholders' equity | $ | 112,728 | $ | 97,747 | ||||
CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (28,349 | ) | $ | (17,754 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
(Recovery of) provision for bad debt expense | (657 | ) | 217 | |||||
Depreciation and amortization | 339 | 565 | ||||||
Amortization of intangible assets | 1,510 | - | ||||||
Share-based compensation | 6,369 | 6,199 | ||||||
Payment-in-kind interest | 1,609 | 490 | ||||||
Amortization of debt issuance costs and original issue discounts | 154 | 60 | ||||||
Amortization of lease right-of-use assets, net of accretion in lease liabilities | 2,260 | 821 | ||||||
Deferred income taxes | (49 | ) | - | |||||
Increase (decrease) in cash resulting from changes in: | ||||||||
Accounts receivable | (811 | ) | 497 | |||||
Inventory, net | (1,202 | ) | (16 | ) | ||||
Prepaid expenses and other current assets | (40 | ) | (696 | ) | ||||
Other assets | (235 | ) | (192 | ) | ||||
Accounts payable and accrued expenses | (268 | ) | (1,515 | ) | ||||
Lease liabilities | (1,321 | ) | (716 | ) | ||||
Contract liabilities | (272 | ) | (69 | ) | ||||
Accrued interest payable | 869 | 264 | ||||||
Net cash used in operating activities | (20,094 | ) | (11,845 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | (996 | ) | (473 | ) | ||||
Net cash used in investing activities | (996 | ) | (473 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from offerings of common stock, net of offering costs | - | 3,263 | ||||||
Proceeds from issuance of note payable, net of financing costs and discount | - | 28,653 | ||||||
Proceeds from stock option exercises | 654 | 49 | ||||||
Payments for taxes related to net share settlement of equity awards | (1,993 | ) | (1,661 | ) | ||||
Proceeds from issuance of common stock under at-the-market equity offering program, net of issuance costs of | 22,020 | - | ||||||
Proceeds from issuance of common stock under employee stock purchase plan | 546 | 311 | ||||||
Net cash provided by financing activities | 21,227 | 30,615 | ||||||
Net change in cash, cash equivalents and restricted cash | 137 | 18,297 | ||||||
Cash, cash equivalents and restricted cash, beginning of period | 46,973 | 20,104 | ||||||
Cash, cash equivalents and restricted cash, end of period | $ | 47,110 | $ | 38,401 | ||||
Cash and cash equivalents | 46,184 | 38,221 | ||||||
Restricted cash included in other current assets and other assets, non-current | 926 | 180 | ||||||
Total cash, cash equivalents and restricted cash | $ | 47,110 | $ | 38,401 | ||||
SUPPLEMENTAL CASH FLOW INFORMATION | ||||||||
Cash paid for: | ||||||||
Income taxes | $ | 34 | $ | 69 | ||||
Interest | $ | 1,609 | $ | 490 | ||||
Non-cash investing and financing transactions: | ||||||||
Property and equipment included in accounts payable and other accrued liabilities | $ | 329 | $ | - | ||||
Net transfers of reusable components between property and equipment and inventory | $ | 307 | $ | 262 | ||||
Right-of-use assets obtained in exchange for operating lease liabilities | $ | 13,882 | $ | 3,309 | ||||
SOURCE: ClearPoint Neuro, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ClearPoint Neuro's third-quarter 2026 revenue and earnings results?
ClearPoint Neuro reported $12.1 million in revenue, up 36% year over year, and a $7.460 million net loss, or $0.24 per share. A year earlier, its net loss was $5.891 million, or $0.21 per share. Revenue growth included acquired IRRAflow products.
What is ClearPoint Neuro's 2026 revenue outlook?
ClearPoint Neuro estimates full-year 2026 revenue of $48.0 million to $50.0 million.
What is ClearPoint Neuro's role in the Dartmouth Health spinal metastases research program?
ClearPoint contributes technical, software development and procedural expertise to Dartmouth Health's five-year, $2.98 million NCI-funded program using the ClearPoint Prism system. The early-stage research advances MRI-guided laser therapy for spinal metastases, progressing from benchtop work through large-subject validation to a clinical trial. The award is not described as funding paid directly to ClearPoint.